Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Amarin has already won rights for first amendment in court. https://www.mintz.com/insights-center/viewpoints/2146/2016-03-11-amarinfda-settlement-significant-first-amendment-victory
Vascepa is already selling in China for high trigs so the reimbursement should already be in place.
Please convey this thought to Amarin
I am getting data from https://opendata.nhsbsa.net/dataset/english-prescribing-data-epd as shared by @CaptBeer , June 2023 data with filter CHEMICAL_SUBSTANCE_BNF_DESCR = "Icosapent"
I did not save Andrew Ambrosy tweet , I guess it was deleted following the termination of the mitigate trial.
Quickly filtered the dataset for Icosapent (Vazkepa ). Looks like prescriptions increased from 79788 in May to 95084 in June.
Waiting for your confirmations and chart presentations.
@CaptBeer English Prescribing Dataset (EPD) for June 2023 is out , Please update your charts and share.
Surely EU glass is not full but at the same time it is not empty too. In EU we have more than half of US population approved without any generic competition , US share is also more then 50% as compared to generics and we also have things in ROW. With 300+ m dollars in cash , the current share price is insane.
Hi Capt , do we have UK data for June 2023 now?
little patience.
Spain approval and MITIGATE ESC late breaker are coming soon.
There was a tweet for Andrew Ambrosy that his presentation is accepted in ESC 2023 , can anyone find/search that on iHub or internet, seems to be deleted
someone posted esc 2023 presentation tweet or message by MITIGATE lead Andrew Ambrosy, M.D or Alan S Go, M.D which is still medically embargoed. Topic should be available as June 6 as late breaker. Please report
Someone please share Amarin brief 03/21/2023 in Amarin/Hikma infringement appeal in U.S. Court of Appeals, Federal Circuit
Thanks Sleven
Please provide the new appeal link.
Thanks
https://www.courtlistener.com/docket/18701895/amarin-pharma-inc-v-hikma-pharmaceuticals-usa-inc/?page=2
Last Updated: March 21, 2023, 7:31 a.m. EDT
This docket was collected as part of the RECAP Project. Therefore, it is updated when users of the RECAP Extension download the docket from PACER. To see the most up to date version of this docket, click the button above to "View on PACER." The date shown here is <strong>not</strong> the date of the latest filing in this case.">March 21, 2023, 7:31 a.m. EDT</span>
Anyone has update on Amarin vs Hikma infringement appeal that has papaers due today March 21 2023
Thanks CaptBeer
Please post without formatting or any format that saves you time. Appreciate your effort to post script numbers.
Hi PDude , I consider you a rational man. There are 3 choices here , ALL White , ALL Blue and some Blue. You say you do not have a problem with 1-2 blue but you choose all whites. Just want to clarify that you do not think this voting is like money and other shareholders with blue money will be able to buy SOME seats and so no need for you to vote any blue. Every board seat is separate and need every vote including yours. Please do not make a voting all white choice just because what you fell about people who are voting all blue. Hope you understand your conscious choice of not voting 1-2 blue which means no change needed and I do not want to know anything.
After all what AMRN and shareholders have gone through years, it is hard for me to believe someone can go all white. I can understand opposite arguments but at least vote for one shareholder representative that can throw some light on the things.
After all what AMRN and shareholders have gone through years, it is hard for me to believe someone can go all white. I can understand opposite arguments but at least vote for one shareholder representative that can throw some light on the things.
In the same boat as you.
AMRN BOD:
Best Case : $10+ Probability:30 Confidence:20 Time:2+Y
Worst Case: $0 Probability:70 Confidance:80 Time:1+Y
Sarissa:
Best Case : $10+ Probability:70 Confidence:80 Time:6M
Worst Case: $4 Probability:30 Confidance:20 Time:6M
Going ALL BLUE
His and also mine and also fellow shareholders immediate plan is to see what AMRN BOD are hiding.
my TG are 60 range. I tried some bad eating habits before my last test but in vain.
wanna see a combined GV column
Even if you have CVD or diabetes , the label is >150 TG. Aetna Express scripts keep denying my doc Vascepa prescription as my TG are way below that. Anybody have experience with low TG and getting Vacsepa
Docket last updated: 02/07/2023 11:59 PM EST
Monday, February 06, 2023
155 misc Disclosure Statement - Rule 7.1 Mon 02/06 11:09 AM
Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Association for Accessible Medicines. (Schladweiler, Benjamin)
Thursday, February 02, 2023
misc Deficiency Notice - No 7.1 Statement Filed Thu 02/02 2:58 PM
DEFICIENCY NOTICE issued by the Court to Association for Accessible Medicines: Pursuant to Fed. R. Civ. P. 7.1 (b)(1), A party must: (1) file the disclosure statement with its first appearance, pleading, petition, motion, response, or other request addressed to the court. Counsel is requested to supplement the docket with an appropriate Rule 7.1 Disclosure Statement. (nms)
Hi north40000 , any update can you get on AMRN vs HIKMA infringement case.
What is AMRN BOD hiding? I am just voting all BLUE to know that.
Hi North , any update to amarin vs hikma filling that was due Jan 20
I am a software developer by profession and a regular guy otherwise. I understand humans are intelligent creatures and some of them overthink and gather different options even when the question is binary with a yes no answer.
Denner initially asked for 2-3 BOD seats on the board which were rejected after a 15 week wait and consideration. AMRN BOD old or new is all the same , they have some plan to present you but they hide their real execution plan (no support to marjac appeal , unneeded sales rep , trashed inventory , free options , no generic vascepa , no usa combo) and totally deny to include any shareholder or activist representative in BOD keeping everyone in the dark.
Now how can you expect a plan from denner when he is in the dark without an BOD representation?
I hope you understand that AMRN has made this an binary choice for you.
Now personally I do not see any issue with double bod size , its still 50/50 balance , its a proposal only and will settle down.
Also I think each individual sarissa bod has a separate line for voting ( maybe , maybe not - will AMRN decide?)
Again the answer needs to be binary so use some techniques like weight/priority to arrive at the conclusion. eg. if your priority is board size with a weight of 10 and you can continue living in the dark , it is your binary choice.
and all that when they have won free speech case with FDA to tell people what is scientifically true.
Happy new year and all the best Marjac
Really good news duke
Lovaza (EPA+DHA) script numbers give me more pain than then generic vascepa (EPA).
HealthNet case is still in progress of discovery documents. Looks like the appeal is against Hikma to include them in the case as only recently final verdict came to free Hikma. Can someone more knowledgeable in legal confirm that?
marjac , tell me you are ready to file for supreme court.